I just bought this pharma stock for its next generation of blockbuster drugs — and its dividend

CNBC - Oct 27, 2026

AbbVie is entering a new chapter of growth, fueled by its blockbuster immunology drugs and expanding neuroscience business. Investor Kevin Simpson shares why he's optimistic.

Read full article

More News

The Daily Feeder

A leading news network dedicated to keeping you up-to-date on the world's most important political, business, and cultural news into a three-minute read.

NEWSLETTER